351532-09-7

Basic information

• Product Name: 2-((1-(4-fluorobenzyl)piperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one
• Synonyms: 2-((1-(4-fluorobenzyl)piperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one
• CAS NO: 351532-09-7
• Molecular Weight: 397.49
• Mol File: 351532-09-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-((1-(4-fluorobenzyl)piperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((1-(4-fluorobenzyl)piperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one(351532-09-7)
• EPA Substance Registry System: 2-((1-(4-fluorobenzyl)piperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one(351532-09-7)

Safety Data

• Hazardous Substances Data: 351532-09-7(Hazardous Substances Data)

Upstream product

• 459-46-1 4-Fluorobenzyl bromide 
• 120014-30-4 debenzyldonepezil 
• 120014-06-4 donepezil 

Relevant articles and documents

Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease

A series of novel donepezil derivatives was designed, synthesized and evaluated as multifunctional acetylcholinesterase (AChE) inhibitors for the treatment of Alzheimer's disease (AD). The screening results indicated that most of the compounds exhibited potent inhibition of AChE with IC50values in the nanomolar range. Moreover, these derivatives displayed good antioxidant, Aβ interaction, blood-brain barrier penetration (PAMPA-BBB+) and ADMET properties (in silico). Among them, 5c demonstrated excellent AChE inhibition (IC50: 85?nM for eeAChE, 73?nM for hAChE), metal chelation, and inhibitory effects on self-induced, hAChE-induced and Cu2+-induced Aβ1-42aggregation (18.5%, 72.4% and 46.3%, at 20?μM). Kinetic analysis and molecular modeling studies suggested that 5c could bind simultaneously to the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE. More importantly, 5c exhibited significant neuroprotective potency against Aβ1-42-induced PC12?cell injury. Furthermore, the step-through passive avoidance test showed 5c significantly reversed scopolamine-induced memory deficit and no hepatotoxicity in mice. These results indicated that 5c might be a promising drug candidate for AD therapy.